Most Parkinson's patients complain about sleep problems. The subjective effect of deep brain stimulation (DBS) of the subthalamic nucleus (STN) on nocturnal disabilities and sleep quality was elucidated by the recently established Parkinson's disease sleep scale (PDSS). The DBS-treated group obtaine
Health-Related quality of life in patients with advanced Parkinson's disease treated with deep brain stimulation of the subthalamic nuclei
✍ Scribed by Helle Just; Karen Ostergaard
- Publisher
- John Wiley and Sons
- Year
- 2002
- Tongue
- English
- Weight
- 69 KB
- Volume
- 17
- Category
- Article
- ISSN
- 0885-3185
No coin nor oath required. For personal study only.
✦ Synopsis
Parkinson's disease (PD) is a progressive neurodegenerative disorder for which there is as yet no cure. It affects many aspects of patients' lives, only some of which can be monitored by available clinical rating scales. In the past decade, there has been a new emphasis on the use of health-related quality of life (HRQOL) measures to describe patient response to treatment. We describe patient-reported HRQOL in subjects who underwent bilateral deep brain stimulation (DBS) of the subthalamic nuclei (STN) for the treatment of PD, compared with a similar group of subjects who did not receive surgical treatment. A consecutive series of patients (n = 11) with advanced idiopathic PD were treated with DBS of the STN. This surgically treated group was compared prospectively with a similar group of patients (n =13) awaiting surgery. Self-reported HRQOL, measured by the Parkinson's Disease Questionnaire (PDQ-39) was evaluated at three time periods T(0), T(3), and T(6). The surgery group was evaluated according to the Unified Parkinson's Disease Rating Sale (UPDRS) before (T(0)), 3 (T(3)), and 6 months (T(6)) after surgery. HRQOL, UPDRS part II and III, duration of off periods, and dyskinesias improved significantly from T(0) to T(3) and from T(0) to T(6) for the surgery group but not for the nonsurgery group. Ten of the 11 patients treated with DBS of the STN reported a lower summary score (indicating better HRQOL) 6 months after surgery. The results of this prospective controlled study suggest that patients with advanced idiopathic PD treated with DBS of the STN obtain significant improvements in patient reported HRQOL and in clinical outcomes 3 and 6 months after surgery.
📜 SIMILAR VOLUMES
## Abstract We investigated gender‐differences in clinical phenomenology and response to deep brain stimulation (DBS) of the subthalamic nucleus (STN) in a group of patients with advanced Parkinson's disease (PD). Thirty‐eight consecutive patients with PD (22 men and 16 women), bilaterally implante
## Abstract We investigated the impact of subthalamic nucleus (STN) deep brain stimulation (DBS) on quality of life (QOL) in patients with advanced Parkinson's disease, as self‐assessed before and after surgery by completing the Parkinson's Disease Questionnaire (PDQ39). In addition to this prospec
## Abstract We evaluated the long‐term effects of subthalamic nucleus (STN) stimulation on health‐related quality of life (HRQL) in patients with advanced Parkinson's disease (PD). STN stimulation improves motor function and decreases medication requirements in patients with advanced PD. The impact
## Abstract Subthalamic nucleus (STN) stimulation improves motor disability and quality of life in patients with advanced Parkinson's disease (PD). Short‐term mortality is low, but little is known about long‐term mortality. We assessed mortality and causes of death in 171 consecutive PD patients tr
## Abstract To determine whether the degree to which a patient with Parkinson's disease expects therapeutic benefit from subthalamic nucleus–deep brain stimulation (STN‐DBS) influences the magnitude of his or her improved motor response, 10 patients with idiopathic Parkinson's and bilateral STN‐DBS